Acura Pharmaceuticals Inc. (ACUR)

[The Rainmaker]

Enough cash for at least 12 months keeping the O/S low and ripe for big news.

At December 31, 2015, the company had cash, cash equivalents and marketable securities totaling $13.3 million and $8 million in term debt financing, excluding debt discount and debt issuance cost. We have sufficient cash to cover our cash requirements through at least the next 12 months, including completion of study AP-LTX-400 or LTX-04, our lead candidate, containing hydromorphone under the LIMITX program, as well as formulations of LTX-03, which is our product containing hydrocodone. And as Bob said, hydrocodone with acetaminophen remains the largest prescribed opioid product in the US.